Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Psoriasis–AD Switching May Mimic Treatment Failure
Recognizing sustained switches between the two diseases can prevent premature discontinuation of effective biologics and point toward Janus kinase inhibitors, a 148-patient cohort suggests.
A study identified persistent phenotype switching between psoriasis and atopic dermatitis during systemic or biologic therapy.
2
Among 148 patients, 101 switched from psoriasis to eczematous features, while 47 switched from atopic dermatitis to psoriasiform disease.
3
Interleukin-17 inhibitors were linked to psoriasis-to-eczematous switching, while dupilumab was primarily associated with atopic dermatitis-to-psoriasiform switching.
4
Janus kinase inhibitors were the most common treatment modification following phenotype switching, with significant clinical improvement observed.
5
The study highlights the need for clinicians to recognize phenotype switching to avoid misclassifying treatment responses as failures.
